Clinical trials
Phase 2 Smoldering Multiple Myeloma trials in the United States
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
30 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 3 |
| 2011 | 3 |
| 2013 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 1 |
| 2019 | 2 |
| 2021 | 3 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 12 |
| Terminated | 7 |
| Active, not recruiting | 6 |
| Recruiting | 4 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Dana-Farber Cancer Institute | 6 |
| National Cancer Institute (NCI) | 3 |
| University of Rochester | 3 |
| City of Hope Medical Center | 2 |
| Barbara Ann Karmanos Cancer Institute | 1 |
| Bristol-Myers Squibb | 1 |
| Emory University | 1 |
| Icahn School of Medicine at Mount Sinai | 1 |
| Innate Pharma | 1 |
| International Myeloma Foundation | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Smoldering Multiple Myeloma | 30 |
| Multiple Myeloma | 12 |
| Monoclonal Gammopathy of Undetermined Significance | 7 |
| Neoplasms, Plasma Cell | 7 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 |
| Neoplasms | 1 |
| Paraproteinemias | 1 |
| Precancerous Conditions | 1 |
| Prostatic Neoplasms | 1 |
Trials
Showing 1 to 25 of 30. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.